Protein Drugs: Market Research Report

Date: August 22, 2010
Pages: 524
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Protein Drugs: Market Research Report
This report analyzes the Global market for Protein Drugs in US$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others (Including Peptide Antibiotics and Enzymes).

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Inc., Alexion Pharmaceuticals, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb Company, Medarex, Inc., Crucell N.V., Dendreon Corporation, Eli Lilly and Company, Emergent BioSolutions, Inc., Genentech, Inc., Johnson & Johnson, Centocor Ortho Biotech, Inc., MedImmune, Inc., Merck Serono S.A., Schering-Plough Corporation, UCB Group, Unigene Laboratories, Inc., and Vaccinogen, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study



A Prelude
Protein Drugs Are the Best Sellers
Key Statistics:

Table 1. World Market for Biopharmaceuticals (2009): Top 10 Brands Ranked by Dollar Sales (In US$ Billion) (includes corresponding Graph/Chart)
Table 2. World Market for Biopharmaceuticals (2007 & 2008): Top 15 Brands Ranked by Dollar Sales (In US$ Billion)

Competitive Scenario
Intensifying Consolidation Activity
Impact of Recession: A Review
Impact of Recession on Drug Sales
Impact of Recession on R&D Activities
Not Recession, But Generic Competition Will Cause Sales Erosion
Patent Expiration
Impending Patent Expiry For Key Protein Drugs
Patent Expirations For Key Protein and Peptide Drugs in the Recent Past
Follow-on Biologics: An Opportunity in Adverse Conditions
Legal and Scientific Viability of Follow-on Protein Drugs
MAb: A Market Better Protected from Generic Competition
Approved Monoclonal Antibodies in the Market
Unmet Medical Needs in Emerging Markets Provides Fertile Environment
Key Market Trends & Issues: A Review
Continuous Fight Against Diseases: A Key Propeller for Growth
Population Aging Makes Rise Of Protein Drugs Inevitable
Ability to Address Wide Gamut of Diseases is Key to Success
Combination Biologics Can Offer New Treatment Possibilities
Shift Towards Humanized and Fully Human Antibodies
Biotechnology Gives a New Direction
Innovative Drug Delivery Methods: The Need of the Hour
Companies Seek Partnerships and Collaborations to Sustain Profit Margins
Increasing Demand for Protein A in Mab Manufacturing
Rising Number of MAbs Under Clinical Trials
Major Protein Drugs in Pipeline As of 2009
Untapped Pharmacological Potential of GPCRs Ignites Interest
Increased Reliance On Contract Manufacturing
Reimbursement & Price Sensitivity Are Key Challenges
Manufacturing Bottleneck
High Costs Impede Penetration
A Special Focus On Key Regional Markets
United States
Market Overview
Biologicals: A Review
Biologicals: A Costly Preposition
Recombinant Proteins To Continue Their Significance as Key Biologic Products
Recombinant Blood-Related Agents to Continue Their Market Growth
Early Generic Competition Will Unsettle Revenues for Key Protein Drugs
Key Statistics:

Table 3. US Market for Protein Therapeutics (2010): Percentage Share Breakdown of Dollar Sales for Key Therapy Area (includes corresponding Graph/Chart)

Market Overview
China to Emerge As Biosimilar Major
Lack of Regulatory Framework
Market Overview
Indian Pharma Companies Gear Up to Grab a Big Slice of Global Follow-On Biologics Market
Openness in US Market Will Provide Opportunities


An Introduction
Structural Information
Classification of Proteins
Sources of Protein Drugs
Types of Protein-Based Drugs
Clotting factors
Monoclonal Antibodies (Mabs)
Different Types of Protein Drugs
Significance of Biotechnology in Protein-Based Drugs
Hybridoma Cell Technology
Recombinant DNA Technology
Production of Protein Drugs through Transgenic Animals
Disadvantages of Protein-based Drugs
Immunogenicity of Protein-Based Drugs


Millipore Launches Magna RIPTM RNA-binding ProteinImmunoprecipitation Kit
Millipore Unveils AllostericProfilerTM Service
Caliper Life Sciences Introduces Two Products to Expand LabChip GX Product Range
BioDtech Introduces EndoPrep
Amgen Introduces Vectibix
Trevigen Introduces Mouse Monoclonal Antibody
UCB Receives FDA Approval for Cimzia®
MD Biosciences Launches Keratocan and Lumican Monoclonal Antibodies
PhyNexus Introduces PhyTip® ProPlus™ Columns


Novartis Vaccines Receives EC Approval for Menveo®
Lonza Takes Over Algonomics
Daicel Chemical Takes Over ChromTech
Roche Licenses ProTek Stabilisation Technology of Aegis Therapeutics
Lonza to Manufacture Arzerra
Sanofi Pasteur Receives FDA Approval for Fluzone® High-Dose Vaccine
Maxygen and Astellas Complete Joint Venture Transaction
Sanofi Pasteur’s Panenza® and Humenza® Vaccines Elicit Strong Immune Response
Amgen Collaborates with GSK
Nabi Biopharmaceuticals Inks Licensing Agreement with GSK
Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance
OPKO Health and Academia Sinica Ink Exclusive License Agreement
Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact
Roche and Covagen Enter into Collaboration
Lonza to Manufacture Biologics for LFB and Medarex
Protgen Establishes Protein Drug Innovation Center in Beijing
National Cheng Kung University Inks MoU with ScinoPharm Taiwan
Novo Nordisk and ZymoGenetics Signs Licensing Agreement
Lipoxen Signs Collaboration Agreement with Pharmasynthez
Debiopharm Group Inks License Agreement with Curis
Bristol-Myers Squibb Acquires Medarex
Sanofi Pasteur Signs Licensing Agreement with Syntiron
Sanofi Pasteur Inks Strategic Agreement with ShanH
Access Pharmaceuticals Acquires Somanta Pharmaceuticals
IMUC Completes Molecular Antibody Technology Acquisition
Callisto Merger Corporation Merges with Celldex Therapeutics
Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
Eusa Sells Antibody Research Business
Dyax and Sanofi-Aventis Sign Agreements
HGS Enters into Antibody Collaboration Agreement with Xencor
Wyeth Pharmaceuticals and Biovitrum Extend ReFacto Supply Agreement
Caprotec Bioanalytics and Merck Ink Collaboration Agreement
Biomonitor Snaps Up Neutekbio
GE Healthcare Takes Over MicroCal
Arana Therapeutics Enters into Collaboration with Greenovation Biotech
Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen
Sanofi Pasteur Holding Purchases Acambis
GlaxoSmithKline Enters into Strategic Alliance with Archemix
Talecris Biotherapeutics Inks License Agreement with Crucell
Polyphor Signs Exclusive Licensing Agreement with Allergan
Morphotek® Enters into Partnership with Pivotal BioSciences
PharmAthene Snaps Up Biodefence Vaccines Business of Avercia Biologics
Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement
MacroGenics Purchases Raven Biotechnologies


Abbott Laboratories, Inc. (US)
Alexion Pharmaceuticals, Inc. (US)
Amgen, Inc. (US)
Biogen Idec (US)
Bristol-Myers Squibb Company (US)
Medarex, Inc. (US)
Crucell N.V. (The Netherlands)
Dendreon Corporation (US)
Eli Lilly and Company (US)
Emergent BioSolutions, Inc. (US)
Genentech, Inc. (US)
Johnson & Johnson (US)
Centocor Ortho Biotech, Inc. (US)
MedImmune, Inc. (US)
Merck Serono S.A. (Switzerland)
Schering-Plough Corporation (US)
UCB Group (Belgium)
Unigene Laboratories, Inc. (US)
Vaccinogen, Inc. (US)


Table 4. World Recent Past, Current & Future Analysis for Protein Drugs by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 5. World 10-Year Perspective for Protein Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009, and 2015
Table 6. World Recent Past, Current and Future Analysis for Protein Drugs by Drug Type – Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 7. World 10-Year Perspective for Protein Drugs by Drug Type – Percentage Breakdown of Dollar Sales for Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)


Total Companies Profiled: 56 (including Divisions/Subsidiaries - 58)
The United States
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Skip to top

Ask Your Question

Protein Drugs: Market Research Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: